Protocols

Martin Shkreli suddenly changes his tune on Clinton threat; Genenta adds $8M for gene therapy R&D

⇨ Looking to stay out of jail ahead of his sentencing on three convictions on felony fraud charges, Martin Shkreli has apologized to the judge in his case for his “awkward attempt at humor” in his Facebook posting offering to pay anyone who grabbed a lock of Hillary Clinton’s hair $5,000. In the letter, Shkreli says he’s a nonviolent person and never intended anyone harm. Federal prosecutors asked the judge to jail him, claiming that Shkreli is a threat that should be behind bars now. CNBC reports that Shkreli took a different approach in responding on Facebook. He wrote: ‘‘F— the government. I will never kiss their ring or snitch. Come at me with your hardest because I haven’t seen anything impressive yet.”

⇨ Milan-based Genenta Science raised an $8 million B round for its work in hematopoietic stem cell gene therapy for tumor treatment. The round was led by Italian, British, and Swiss private investors, family offices, and business angels, its Series A investors and Board Members. Genenta, led by CEO Pierluigi Paracchi, has raised more than $20 million for its work to date. Novartis vet Guido Guidi joined the board and Dana-Farber’s Ken Anderson joined the scientific advisory group at the company.

⇨ Alexion will have to pay something of a fine before it moves its headquarters from New Haven, CT to Boston. The company got $26 million from the state in a loan and a grant for being based there, reports the Hartford Courant, and now officials say the biotech will have to repay that — along with penalties.

⇨ The UK’s Clinigen Group has struck a deal to acquire Quantum Pharma for 150 million pounds.

Bayer has turned to Berkeley Lights’ Beacon platform to automate biological workflows and gain efficiencies in its drug development process.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biomanufacturing